{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:41:47Z","timestamp":1762342907865,"version":"build-2065373602"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Carboplatin resistance represents a critical therapeutic challenge in non-small cell lung cancer (NSCLC) treatment. Although KHSRP has been implicated in lung cancer progression, its molecular mechanisms and impacts on chemotherapy sensitivity remain elusive. Notably, KHSRP has the capacity to activate the transcription of HMGB1, an oncogene known to influence chemotherapy sensitivity. However, it remains to be determined whether KHSRP affects chemotherapy response in NSCLC via HMGB1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>KHSRP expression in NSCLC cells was analyzed using qRT-PCR. Cell proliferation, apoptosis, and migration were evaluated using colony formation, flow cytometry and wound healing assays. A luciferase reporter assay was conducted to assess whether KHSRP transcriptionally regulates HMGB1. Additionally, A549 cell xenografts were established in nude mice to investigate the tumor growth-promoting effects of KHSRP in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>KHSRP expression was notably elevated in NSCLC cells. Overexpression of KHSRP remarkably promoted A549 cell proliferation, migration, and epithelial-mesenchymal transition (EMT); while KHSRP knockdown exhibited the opposite effects. Mechanically, KHSRP notably promoted the transcription of HMGB1 and upregulated its expression in A549 cells. Importantly, deficiency of KHSRP remarkably enhanced the suppressive effects of carboplatin on A549 cell proliferation, migration, EMT and HMGB1 expression. Meanwhile, in vivo experiments demonstrated that downregulation of KHSRP potentiated the inhibitory effect of carboplatin on tumor growth in tumor-bearing nude mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings demonstrate that silencing of KHSRP enhances the drug sensitivity of carboplatin in NSCLC, potentially mediated through the inhibition of HMGB1. Targeting KHSRP may represent a promising therapeutic strategy to improve chemotherapy efficacy in NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41065-025-00584-4","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:38:15Z","timestamp":1762342695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Downregulation of KHSRP enhances carboplatin sensitivity in non-small cell lung cancer"],"prefix":"10.1186","volume":"162","author":[{"given":"Bao","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuguang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luri","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanhui","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bateer","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"3","key":"584_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"584_CR2","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1056\/NEJMra0802714","volume":"359","author":"RS Herbst","year":"2008","unstructured":"Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367\u201380. https:\/\/doi.org\/10.1056\/NEJMra0802714.","journal-title":"N Engl J Med"},{"issue":"2","key":"584_CR3","doi-asserted-by":"publisher","first-page":"188636","DOI":"10.1016\/j.bbcan.2021.188636","volume":"1876","author":"T Singh","year":"2021","unstructured":"Singh T, Fatehi Hassanabad M, Fatehi Hassanabad A. Non-small cell lung cancer: emerging molecular targeted and immunotherapeutic agents. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188636. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188636.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"12","key":"584_CR4","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of Incidence, Prevalence, Survival, and initial treatment in patients with Non-Small cell lung cancer in the US. JAMA Oncol. 2021;7(12):1824\u201332. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4932.","journal-title":"JAMA Oncol"},{"issue":"Suppl 5","key":"584_CR5","doi-asserted-by":"publisher","first-page":"v103","DOI":"10.1093\/annonc\/mdq207","volume":"21","author":"L Crino","year":"2010","unstructured":"Crino L, Weder W, van Meerbeeck J, Felip E, Group EGW. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v103\u201315. https:\/\/doi.org\/10.1093\/annonc\/mdq207.","journal-title":"Ann Oncol"},{"issue":"8","key":"584_CR6","doi-asserted-by":"publisher","first-page":"e32899","DOI":"10.1097\/MD.0000000000032899","volume":"102","author":"Y Alduais","year":"2023","unstructured":"Alduais Y, Zhang H, Fan F, Chen J, Chen B. Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. Medicine. 2023;102(8):e32899. https:\/\/doi.org\/10.1097\/MD.0000000000032899.","journal-title":"Medicine"},{"issue":"Suppl 4","key":"584_CR7","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192\u2013237. https:\/\/doi.org\/10.1093\/annonc\/mdy275.","journal-title":"Ann Oncol"},{"issue":"30","key":"584_CR8","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","volume":"35","author":"N Hanna","year":"2017","unstructured":"Hanna N, Johnson D, Temin S, Baker S Jr., Brahmer J, Ellis PM, et al. Systemic therapy for stage IV Non-Small-Cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35(30):3484\u2013515. https:\/\/doi.org\/10.1200\/JCO.2017.74.6065.","journal-title":"J Clin Oncol"},{"issue":"24","key":"584_CR9","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542\u201350. https:\/\/doi.org\/10.1056\/NEJMoa061884.","journal-title":"N Engl J Med"},{"issue":"5","key":"584_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.molcel.2004.05.002","volume":"14","author":"R Gherzi","year":"2004","unstructured":"Gherzi R, Lee KY, Briata P, Wegmuller D, Moroni C, Karin M, et al. A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol Cell. 2004;14(5):571\u201383. https:\/\/doi.org\/10.1016\/j.molcel.2004.05.002.","journal-title":"Mol Cell"},{"issue":"4","key":"584_CR11","doi-asserted-by":"publisher","first-page":"e61915","DOI":"10.1371\/journal.pone.0061915","volume":"8","author":"J Yang","year":"2013","unstructured":"Yang J, Fan J, Li Y, Li F, Chen P, Fan Y, et al. Genome-wide RNAi screening identifies genes inhibiting the migration of glioblastoma cells. PLoS ONE. 2013;8(4):e61915. https:\/\/doi.org\/10.1371\/journal.pone.0061915.","journal-title":"PLoS ONE"},{"issue":"3","key":"584_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/15384101.2020.1870820","volume":"20","author":"XY Yao","year":"2021","unstructured":"Yao XY, Liu JF, Luo Y, Xu XZ, Bu J. LncRNA HOTTIP facilitates cell proliferation, invasion, and migration in osteosarcoma by interaction with PTBP1 to promote KHSRP level. Cell Cycle (Georgetown Tex). 2021;20(3):283\u201397. https:\/\/doi.org\/10.1080\/15384101.2020.1870820.","journal-title":"Cell Cycle (Georgetown Tex)"},{"issue":"2","key":"584_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.18632\/oncotarget.27413","volume":"11","author":"K Taniuchi","year":"2020","unstructured":"Taniuchi K, Ogasawara M. KHSRP-bound small nucleolar RNAs associate with promotion of cell invasiveness and metastasis of pancreatic cancer. Oncotarget. 2020;11(2):131\u201347. https:\/\/doi.org\/10.18632\/oncotarget.27413.","journal-title":"Oncotarget"},{"issue":"1\u20132","key":"584_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11010-016-2806-y","volume":"422","author":"L Tong","year":"2016","unstructured":"Tong L, Luo Y, Wei T, Guo L, Wang H, Zhu W, et al. KH-type splicing regulatory protein (KHSRP) contributes to tumorigenesis by promoting miR-26a maturation in small cell lung cancer. Mol Cell Biochem. 2016;422(1\u20132):61\u201374. https:\/\/doi.org\/10.1007\/s11010-016-2806-y.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"584_CR15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s13046-019-1479-2","volume":"38","author":"M Yan","year":"2019","unstructured":"Yan M, Sun L, Li J, Yu H, Lin H, Yu T, et al. RNA-binding protein KHSRP promotes tumor growth and metastasis in non-small cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):478. https:\/\/doi.org\/10.1186\/s13046-019-1479-2.","journal-title":"J Exp Clin Cancer Res"},{"issue":"18","key":"584_CR16","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.1074\/jbc.M116.757906","volume":"292","author":"RK Bikkavilli","year":"2017","unstructured":"Bikkavilli RK, Zerayesus SA, Van Scoyk M, Wilson L, Wu PY, Baskaran A, et al. K-homology splicing regulatory protein (KSRP) promotes post-transcriptional destabilization of Spry4 transcripts in non-small cell lung cancer. J Biol Chem. 2017;292(18):7423\u201334. https:\/\/doi.org\/10.1074\/jbc.M116.757906.","journal-title":"J Biol Chem"},{"key":"584_CR17","doi-asserted-by":"publisher","unstructured":"Wang Q, Sun Z, Du L, Xu C, Wang Y, Yang B, et al. Melatonin sensitizes human colorectal cancer cells to gamma-ray ionizing radiation in vitro and in vivo. Int J Mol Sci. 2018;19(12):3974. https:\/\/doi.org\/10.3390\/ijms19123974","DOI":"10.3390\/ijms19123974"},{"issue":"3","key":"584_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/BS9.0000000000000122","volume":"4","author":"J Xu","year":"2022","unstructured":"Xu J, Wang D, Ma H, Zhai X, Huo Y, Ren Y, et al. KHSRP combines transcriptional and posttranscriptional mechanisms to regulate monocytic differentiation. Blood Sci. 2022;4(3):103\u201315. https:\/\/doi.org\/10.1097\/BS9.0000000000000122.","journal-title":"Blood Sci"},{"issue":"12","key":"584_CR19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41577-023-00894-6","volume":"23","author":"D Tang","year":"2023","unstructured":"Tang D, Kang R, Zeh HJ, Lotze MT. The multifunctional protein HMGB1: 50 years of discovery. Nat Rev Immunol. 2023;23(12):824\u201341. https:\/\/doi.org\/10.1038\/s41577-023-00894-6.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"584_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s12276-022-00736-w","volume":"54","author":"R Chen","year":"2022","unstructured":"Chen R, Kang R, Tang D. The mechanism of HMGB1 secretion and release. Exp Mol Med. 2022;54(2):91\u2013102. https:\/\/doi.org\/10.1038\/s12276-022-00736-w.","journal-title":"Exp Mol Med"},{"key":"584_CR21","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.2147\/OTT.S104409","volume":"9","author":"Q Xia","year":"2016","unstructured":"Xia Q, Xu J, Chen H, Gao Y, Gong F, Hu L, et al. Association between an elevated level of HMGB1 and non-small-cell lung cancer: a meta-analysis and literature review. Onco Targets Ther. 2016;9:3917\u201323. https:\/\/doi.org\/10.2147\/OTT.S104409.","journal-title":"Onco Targets Ther"},{"key":"584_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/5584_2015_115","volume":"852","author":"K Jakubowska","year":"2015","unstructured":"Jakubowska K, Naumnik W, Niklinska W, Chyczewska E. Clinical significance of HMGB-1 and TGF-beta level in serum and BALF of advanced Non-Small cell lung cancer. Adv Exp Med Biol. 2015;852:49\u201358. https:\/\/doi.org\/10.1007\/5584_2015_115.","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"584_CR23","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.7314\/apjcp.2014.15.12.4865","volume":"15","author":"JL Wang","year":"2014","unstructured":"Wang JL, Wu DW, Cheng ZZ, Han WZ, Xu SW, Sun NN. Expression of high mobility group box - B1 (HMGB-1) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC). Asian Pac J Cancer Prevention: APJCP. 2014;15(12):4865\u20139. https:\/\/doi.org\/10.7314\/apjcp.2014.15.12.4865.","journal-title":"Asian Pac J Cancer Prevention: APJCP"},{"key":"584_CR24","doi-asserted-by":"publisher","first-page":"6916797","DOI":"10.1155\/2018\/6916797","volume":"2018","author":"X Wu","year":"2018","unstructured":"Wu X, Wang W, Chen Y, Liu X, Wang J, Qin X, et al. Glycyrrhizin suppresses the growth of human NSCLC cell line HCC827 by downregulating HMGB1 level. Biomed Res Int. 2018;2018:6916797. https:\/\/doi.org\/10.1155\/2018\/6916797.","journal-title":"Biomed Res Int"},{"key":"584_CR25","doi-asserted-by":"publisher","first-page":"153303382094805","DOI":"10.1177\/1533033820948054","volume":"19","author":"XH Wang","year":"2020","unstructured":"Wang XH, Zhang SY, Shi M, Xu XP. HMGB1 promotes the proliferation and metastasis of lung cancer by activating the Wnt\/beta-Catenin pathway. Technol Cancer Res Treat. 2020;19:1533033820948054. https:\/\/doi.org\/10.1177\/1533033820948054.","journal-title":"Technol Cancer Res Treat"},{"key":"584_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jare.2023.12.020","volume":"66","author":"W Shen","year":"2024","unstructured":"Shen W, Lyu Q, Yi R, Sun Y, Zhang W, Wei T, et al. HMGB1 promotes chemoresistance in small cell lung cancer by inducing PARP1-related nucleophagy. J Adv Res. 2024;66:165\u201380. https:\/\/doi.org\/10.1016\/j.jare.2023.12.020.","journal-title":"J Adv Res"},{"issue":"5","key":"584_CR27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.5301\/tj.5000656","volume":"104","author":"Y Ma","year":"2018","unstructured":"Ma Y, Kang S, Wu X, Han B, Jin Z, Guo Z. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells. Tumori. 2018;104(5):338\u201343. https:\/\/doi.org\/10.5301\/tj.5000656.","journal-title":"Tumori"},{"issue":"6","key":"584_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21(6):341\u201352. https:\/\/doi.org\/10.1038\/s41580-020-0237-9.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"584_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178\u201396. https:\/\/doi.org\/10.1038\/nrm3758.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"584_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1124\/jpet.113.203471","volume":"345","author":"S Mateen","year":"2013","unstructured":"Mateen S, Raina K, Agarwal C, Chan D, Agarwal R. Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with Inhibition of migration and invasion of human non-small cell lung cancer cells. J Pharmacol Exp Ther. 2013;345(2):206\u201314. https:\/\/doi.org\/10.1124\/jpet.113.203471.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"584_CR31","doi-asserted-by":"publisher","first-page":"e57692","DOI":"10.1371\/journal.pone.0057692","volume":"8","author":"X Zhang","year":"2013","unstructured":"Zhang X, Liu G, Kang Y, Dong Z, Qian Q, Ma X. N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines. PLoS ONE. 2013;8(3):e57692. https:\/\/doi.org\/10.1371\/journal.pone.0057692.","journal-title":"PLoS ONE"},{"issue":"1","key":"584_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3727\/096504014X14098532393473","volume":"22","author":"W Shen","year":"2014","unstructured":"Shen W, Pang H, Liu J, Zhou J, Zhang F, Liu L, et al. Epithelial-mesenchymal transition contributes to docetaxel resistance in human non-small cell lung cancer. Oncol Res. 2014;22(1):47\u201355. https:\/\/doi.org\/10.3727\/096504014X14098532393473.","journal-title":"Oncol Res"},{"issue":"7","key":"584_CR33","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1158\/1541-7786.MCR-13-0019-T","volume":"11","author":"SY Cui","year":"2013","unstructured":"Cui SY, Huang JY, Chen YT, Song HZ, Feng B, Huang GC, et al. Let-7c governs the acquisition of chemo- or radioresistance and epithelial-to-mesenchymal transition phenotypes in docetaxel-resistant lung adenocarcinoma. Mol Cancer Research: MCR. 2013;11(7):699\u2013713. https:\/\/doi.org\/10.1158\/1541-7786.MCR-13-0019-T.","journal-title":"Mol Cancer Research: MCR"},{"key":"584_CR34","doi-asserted-by":"publisher","unstructured":"Hou C, Lu M, Lei Z, Dai S, Chen W, Du S et al. HMGB1 positive feedback loop between cancer cells and Tumor-Associated macrophages promotes osteosarcoma migration and Invasion. Laboratory investigation; a journal of technical methods and pathology. 2023;103(5):100054. https:\/\/doi.org\/10.1016\/j.labinv.2022.100054","DOI":"10.1016\/j.labinv.2022.100054"},{"issue":"1","key":"584_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12967-023-03918-w","volume":"21","author":"X Gao","year":"2023","unstructured":"Gao X, Zhou S, Qin Z, Li D, Zhu Y, Ma D. Upregulation of HMGB1 in tumor-associated macrophages induced by tumor cell-derived lactate further promotes colorectal cancer progression. J Translational Med. 2023;21(1):53. https:\/\/doi.org\/10.1186\/s12967-023-03918-w.","journal-title":"J Translational Med"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-025-00584-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:38:16Z","timestamp":1762342696000},"score":1,"resource":{"primary":{"URL":"https:\/\/hereditasjournal.biomedcentral.com\/articles\/10.1186\/s41065-025-00584-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["584"],"URL":"https:\/\/doi.org\/10.1186\/s41065-025-00584-4","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the animal experiments were complied with the guidelines of the Tianjin Medical Experimental Animal Care, and animal protocols were approved by the Institutional Animal Care and Use Committee of Yi Shengyuan Gene Technology (Tianjin) Co. Lted. (protocol number YSY-DWLL-2024726).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No conflicts of interest to report.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"224"}}